Showing results (331-340 of 468) with videos related to

Sort By:
Pageof 47
The American Journal of Clinical Nutrition|June 5, 1999
Hypermetabolism in clinically stable patients with liver cirrhosisM J Müller, J Böttcher, O Selberg, et al.
Journal of Hepatology|December 1, 1996
Identification of cyclin A as a molecular target of antinuclear antibodies (ANA) in hepatic and non-hepatic autoimmune diseasesC P Strassburg, B Alex, F Zindy, et al.
Lancet (London, England)|December 14, 1996
Association between fulminant hepatic failure and a strain of GBV virus CS Heringlake, S Osterkamp, C Trautwein, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|June 23, 2005
Development of an in vitro system for the study of allergens and allergen-specific immunoglobulin E and immunoglobulin G: Fcepsilon receptor I supercross-linking is a possible new mechanism of immunoglobulin G-dependent enhancement of type I allergic reactionsG Sellge, S Laffer, C Mierke, et al.
Infection|December 18, 2007
Clearance of chronic HCV infection during acute delta hepatitisK Deterding, S V Pothakamuri, V Schlaphoff, et al.
Transplantation Proceedings|May 28, 2005
Retrospective analysis of the impact of immunosuppression on the course of recurrent hepatitis C after liver transplantationM J Bahr, J G P Beckermann, K Rifai, et al.
British Journal of Cancer|May 5, 2005
Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patientsT F Greten, F Papendorf, J S Bleck, et al.
Gut|March 20, 1998
Clinical outcome of transfemoral embolisation in patients with arteriovenous malformations of the liver in hereditary haemorrhagic telangiectasia (Weber-Rendu-Osler disease)M Caselitz, S Wagner, A Chavan, et al.
Journal of Hepatology|March 6, 1999
Familial Amyloidotic Polyneuropathy: domino liver transplantationH H Schmidt, B Nashan, M J Pröpsting, et al.
Alimentary Pharmacology & Therapeutics|December 6, 2017
Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosisF Mettke, B Schlevogt, K Deterding, et al.
Pageof 47